Chelsea Therapeutics, Inc. (CHTP) Release: NORTHERA™ Clinical Trial Data Published in Neurology
6/20/2014 8:28:30 AM
CHARLOTTE, N.C., June 19, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter, multinational, double-blind, randomized, placebo-controlled, parallel-group study of NORTHERATM (droxidopa) that details how NORTHERA demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH).
Help employers find you! Check out all the jobs and post your resume.
comments powered by